Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share capital.

Between 2 April and 28 May 2026, Dr. Tong acquired 1.26 million shares in the open market via his wholly owned KT International Investment Limited for approximately HK$3.32 million, translating to an average price of HK$2.63 per share and a trading range of HK$2.23–2.89 per share. In addition, he exercised 1.25 million restricted share units vested on 31 March 2026 at a cost of about HK$1.09 million.

Post-transaction, the company confirmed that its public float remains above the regulatory minimum. Dr. Tong cited confidence in Kintor Pharmaceutical’s clinical progress and commercialization of innovative topical drugs, particularly its anti-hair-loss and hair-regrowth pipeline, and indicated that further share purchases could be considered in accordance with applicable regulations.